Aurobindo Pharma surges on aiming to invest $200 million on Capex in FY20

Aurobindo Pharma is currently trading at Rs. 622.95, up by 6.65 points or 1.08% from its previous closing of Rs. 616.30 on the BSE.

The scrip opened at Rs. 621.00 and has touched a high and low of Rs. 625.50 and Rs. 615.40 respectively. So far 16667 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 838.00 on 30-Apr-2019 and a 52 week low of Rs. 566.00 on 19-Jul-2018.

Last one week high and low of the scrip stood at Rs. 655.00 and Rs. 603.30 respectively. The current market cap of the company is Rs. 36420.51 crore.

The promoters holding in the company stood at 51.87%, while Institutions and Non-Institutions held 35.16% and 12.97% respectively.

Aurobindo Pharma is eyeing to invest up to $200 million on Capex and over five percent of sale value on Research and Development (R&D) during the current financial year. The majority of the CAPEX should be in terms of creating certain both finished dosage and API capacities.

The company had spent $225 million on capex last year and R&D expenditure was at Rs 872 crore or 4.5 percent of the revenues for the year.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

! Get Stock Cash tips with 2 Day’s free trial, our offers, demo calls, our best Services click a link or watch more – Stock Cash Trading Tips

Please follow and like us:
20